@NetworkPrcsg Profile picture

PRCSG_network

@NetworkPrcsg

The mission of the PRCSG is to conduct high quality clinical trials, of therapeutic agents, in children with rheumatic diseases.

Similar User
CARRA photo

@carrainc

Cuoghi Edens photo

@CuoghiE

Sampath Prahalad MD MS photo

@Prahalpedrheum

Ekemini Ogbu MD MSc photo

@PRheumdoc

Ginger Lee photo

@GingerLeeMD

Jay Mehta photo

@jaymehtamd

Jordan Roberts MD MPH photo

@jordanrobertsMD

Dr. Rae Yeung photo

@DrRaeYeung

Sheila Angeles-Han photo

@STHanMD

Dori Abel, MD MSHP photo

@DrDNAbel

Melissa Argraves, MD, MSEd photo

@Rheum2GrowMD

Daniel H Glaser MD, MPH photo

@DanielGlaserMD

Sarah Bayefsky photo

@SarahBayefskyMD

Sabrina Gmuca, MD MSCE photo

@SabrinaGmucaMD

Intravenous Golimumab in Children With Polyarticular-Course Juvenile Idiopathic Arthritis: Long-Term Extension of an Open-Label Phase III Study jrheum.org/content/51/11/…


We invite you to join us for a late breaking poster presentation on Safety and Efficacy of tofacitinib with sJIA @ACRheum on November 18. Poster L09: November 18, 2024, 10:30 AM – 12:30 PM, Poster Session C, (L01-L14) Late Breaking Posters


We invite you to join us for a poster presentation on PK of ustekinumab in Juvenile Psoriatic Arthritis @ACRheum on November 16. Poster 0384: November 16, 2024, 10:30 AM – 12:30 PM, Poster Session A, Pediatric Rheumatology – Clinical Poster I


Intravenous Golimumab in Children with Polyarticular-Course Juvenile Idiopathic Arthritis: Long-term Extension of an Open-label, Phase 3 Study jrheum.org/content/early/…


ACR Convergence 2023: Please join us as an update on the PRCSG network will be given during the Pediatric Rheumatology Committee meeting. The meeting will be held Sunday, November 12th from 10 – 11 am PT at the San Diego Marriott, Grand Ballroom 4.


📢We are excited to announce that Michael Shishov, MD has been elected to serve as the Scientific Director-elect on the Advisory Board. Welcome!


The Systemic Lupus Erythematosus International Collaborating Clinics (SLICC), American College of Rheumatology (ACR), and Lupus Foundation of America (LFA) Damage Index Revision - Item Generation Phase acrabstracts.org/abstract/the-s…


Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study acrabstracts.org/abstract/baric…


Long-term Efficacy and Safety of Subcutaneous Tocilizumab in Patients with Polyarticular or Systemic Juvenile Idiopathic Arthritis – an Extension Study of 2 Phase 1b Clinical Trials acrabstracts.org/abstract/long-…


Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study acrabstracts.org/abstract/effic…


POS0278 EFFICACY AND SAFETY OF SECUKINUMAB IN JUVENILE IDIOPATHIC ARTHRITIS: INTERIM RESULTS FROM THE EXTENSION OF THE JUNIPERA TRIAL ard.bmj.com/content/82/Sup…


OP0164 SAFETY AND EFFICACY OF UPADACITINIB FOR PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS: AN INTERIM ANALYSIS OF AN OPEN-LABEL, PHASE 1 TRIAL ard.bmj.com/content/82/Sup…


POS0751 PHARMACOKINETICS OF UPADACITINIB IN PEDIATRIC PATIENTS WITH POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS ard.bmj.com/content/82/Sup…


Loading...

Something went wrong.


Something went wrong.